Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects

NCT03618095 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT03618095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03618095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Terminated
Start date
January 14, 2019
Completion date
March 31, 2021
Enrollment
382 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

aortic valve stenosis